There is still venture capital out there for early-stage biopharma firms, and some are able to secure significant chunks even at series A.
There is still venture capital out there for early-stage biopharma firms, and some are able to secure significant chunks even at series A.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
